Summary of Utilization Management (UM) Program Changes

March 2020

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
Asceniv	Immune globulins, intravenous	Indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID). Asceniv will be added to the existing Immune Globulins guideline with criteria that mirrors the other intravenous immune globulin products.	New	06/01/2020
Xembify	Immune globulins, subcutaneous	Indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. Xembify will be added to the existing Immune Globulins guideline with criteria that mirrors the other subcutaneous immune globulin products.	New	06/01/2020
Clovique	trientene	New generic trientene product approved for the same indication as Syprine: treatment of patients with Wilson's disease who are intolerant of penicillamine.	New	06/01/2020

		Clovique will be added to the Copper Chelating Agents guideline with criteria to mirror brand Syprine.		
Crysvita	lenvatinib	Expanded indication for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older. (Previous age range was 1 year of age and older.) PA guideline has been updated to include criteria that allows use in patients 6 months of age and older.	Update	04/27/2020
Nucala	burosumab	Expanded indication for patients 6 years and older as add-on maintenance treatment of patients with severe asthma with an eosinophilic phenotype. Previous lower age was 12 years old. PA guidelines will be updated to allow use in patients 6 years of age and older.	Update	06/01/2020
Ultomiris	ravulizumab	Indicated for the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). The PA guideline will be updated with criteria for this new indication. Initial criteria requires a diagnosis of atypical hemolytic uremic syndrome (aHUS). Reauthorization requires documentation of positive clinical response (e.g., hemoglobin stabilization, decrease in the number of red blood cell transfusions) to Ultomiris therapy.	Update	06/01/2020

Dupixent	dupilumab	For the chronic rhinosinusitis with nasal polyposis indication, will be adding an option for an otolaryngologist prescriber. Criteria will now read: Prescribed by or in consultation with an allergist/immunologist or otolaryngologist.	Update	06/01/2020
Rizurgi, Firdapse	amifampridine	Removal of the criterion that states "patient has moderate to severe weakness that interferes with function." Replaced this criterion with "Documentation of symptomatic Lambert-Eaton myasthenic syndrome that interfere with daily functions (e.g., difficulty climbing stairs, walking up steep hills)."	Update	06/01/2020
Siklos	hydroxyurea	As a point of clarification, criteria will be reworded to make it more clear that Siklos is to be used in patients 2 years of age or older (previously criteria stated patients greater than 2 years of age).	Update	06/01/2020
Soliris	eculizumab	Due to the new indication approval for Ultomiris for atypical hemolytic uremic syndrome (aHUS), we will be modifying the Soliris aHUS criteria to include a trial of Ultomiris first. This requirement is already part of the criteria for another indication of paroxysmal nocturnal hemoglobinuria (PNH).	Update	06/01/2020
Halaven	eribulin	To improve clarity, will be adding examples of anthracycline-containing regimens within the criteria.	Update	06/01/2020
Stivarga	regorafenib	To improve clarity, will be adding examples of fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy within the criteria.	Update	06/01/2020
Zelnorm	tegaserod	PA criteria will require a trial of lactulose or polyethylene glycol, AND Linzess.	Update	06/01/2020
Brukinsa	Zanubrutinib	PA criteria require a diagnosis of relapsed or refractory mantle cell	New	04/27/2020

		lymphoma, a trial of a rituximab and chemotherapy treatment, and prescribed by an oncologist.		